Table 2: Previous studies on the performances of CoaguChek XS Plus system.

StudyNumber of measurementsSettingLaboratory-based systemComparison using Bland-Altman plot,
mean bias (95% limit of agreement)

Deom et al. (2009) [13]259Community setting
(38 doctor’s offices)
Innovin (Siemens/Dade-Behring) 0.03 INR (−0.67 INR ~ 0.74 INR)
Urwyler et al. (2009) [14]227Perioperative settingInnovin (Siemens/Dade-Behring) 2.3% (95% CI = −20.3% ~ 24.9%)
Donaldson et al. (2010) [10]52Pharmacist-managed anticoagulation clinicStago (Diagnostica-stago) 0.27 INR (−0.33 INR ~ 0.88 INR)
Celenza and Skinner (2011) [15]293Emergency departmentNot specified−0.0 INR (−1.1 INR ~ 1.1 INR)
Lawrie et al. (2012) [16]168 for innovin and 115 for PT-Fib HS+Overanticoagulated (INR > 4.5) patients in anticoagulation clinicInnovin (Siemens/Dade-Behring) on CA-7000 analyzer (Sysmex) and PT-Fib HS+ (Instrumentation Laboratory) on CA-1500 analyzer (Sysmex)Innovin:
−0.1% (−22.0% ~ 22.1%)
PT-Fib HS+:
8.2% (−21.4% ~ 37.9%)
Urwyler et al. (2012) [17]73Pediatric intensive care unit settingInnovin (Siemens/Dade-Behring)1.22% (−27% ~ 56%)

Abbreviations: INR: international normalized ratio; SD: standard deviation; CI: confidence interval; PT-Fib HS+: HemosIL PT-Fibrinogen HS Plus.